Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mafalda Oliveira

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Breast Cancer Research and Treatment|August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancerVandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast CancerMaura N Dickler, Cristina Saura, Donald A Richards, et al.
NPJ Breast Cancer|November 26, 2021
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trialTomás Pascual, Mafalda Oliveira, Patricia Villagrasa, et al.
Future Oncology (London, England)|July 8, 2020
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancerTomas Pascual, Juan M Cejalvo, Mafalda Oliveira, et al.
EMBO Molecular Medicine|March 27, 2025
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunityBo He, Kira H Wood, Zhi-Jie Li, et al.
NPJ Precision Oncology|November 21, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenograftsAndreu Òdena, Laia Monserrat, Fara Brasó-Maristany, et al.
NPJ Breast Cancer|July 8, 2017
The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international groupMarion Maetens, David Brown, Alexandre Irrthum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trialMafalda Oliveira, Eva Ciruelos, Guillermo Villacampa, et al.
Frontiers in Oncology|November 22, 2021
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 StudySonia Pernas, Patricia Villagrasa, Ana Vivancos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Breast Cancer Research and Treatment|August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancerVandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast CancerMaura N Dickler, Cristina Saura, Donald A Richards, et al.
NPJ Breast Cancer|November 26, 2021
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trialTomás Pascual, Mafalda Oliveira, Patricia Villagrasa, et al.
Future Oncology (London, England)|July 8, 2020
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancerTomas Pascual, Juan M Cejalvo, Mafalda Oliveira, et al.
EMBO Molecular Medicine|March 27, 2025
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunityBo He, Kira H Wood, Zhi-Jie Li, et al.
NPJ Precision Oncology|November 21, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenograftsAndreu Òdena, Laia Monserrat, Fara Brasó-Maristany, et al.
NPJ Breast Cancer|July 8, 2017
The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international groupMarion Maetens, David Brown, Alexandre Irrthum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trialMafalda Oliveira, Eva Ciruelos, Guillermo Villacampa, et al.
Frontiers in Oncology|November 22, 2021
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 StudySonia Pernas, Patricia Villagrasa, Ana Vivancos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Pageof 12